Trends in Pharmacological Sciences
ReviewConstitutive activity of the histamine H3 receptor
Introduction
Current models of G-protein-coupled receptor (GPCR) activation assume that receptors exist in equilibrium between inactive and active conformations. Active conformations are promoted by agonists but also exist in the absence of an agonist (see Glossary), thereby leading to constitutive (or spontaneous) receptor activity. The level of constitutive activity depends on both the number of spontaneously active conformations and the coupling efficiency of these conformations to G proteins. It therefore depends not only on the receptor, but also on the response. Inverse agonists abrogate constitutive activity by promoting inactive conformations. Their maximal effect is correlated to the level of constitutive activity. This direct relationship explains why constitutive activity was first observed for recombinant receptors that were overexpressed and/or mutated 1, 2. Although indirect indications also suggested that constitutive activity of native GPCRs occurs in tissues [3], the physiological relevance of the process was initially debated because of the potential contribution of endogenous agonists to the activity observed.
After the discovery of constitutive activity, the concept of ‘protean agonism’ (named after Proteus, a Greek god who could change shape at will) was introduced on theoretical grounds [4]. The rationale was that the reversal from agonism to inverse agonism occurred when the conformation induced by an agonist showed an efficacy lower than that of the constitutively active conformation of the receptor in the same system. It was therefore predicted that a protean agonist could act as either an agonist or an inverse agonist at the same GPCR, depending on the level of constitutive activity. Protean agonism has been subsequently reported in cell lines expressing various GPCRs such as α2A-adrenoceptors 5, 6, β2-adrenoceptors [7], secretin receptors [8], lysophosphatidic acid receptor-1 [9] and cannabinoid CB2 receptors [10]. Until recently, however, the process remained to be observed under physiological conditions.
The histamine H3 receptor (H3R) was identified in 1983 as an autoreceptor located on histamine-containing nerve endings that controls histamine synthesis and release in the brain 11, 12, 13. The design of selective ligands showed that H3Rs provide the main mechanism for the physiological regulation of histamine neuron activity 13, 14. These selective ligands have been subsequently used in hundreds of studies to modify the activity of histamine-containing neurons, and thereby to disclose their functions. Such studies have shown that H3Rs are involved in the histamine-mediated regulation of important processes such as arousal, cognitive processes and food intake 14, 15, 16.
Not all cerebral H3Rs are autoreceptors. Presynaptic H3 heteroreceptors inhibit the release of various neurotransmitters 14, 17, and postsynaptic H3Rs are located on the perikarya of many neuronal populations [18]. The physiological role of these H3Rs remains, however, unknown.
The H3R was cloned in humans in 1999 [19]. This cloning was an important step for molecular studies and drug design. Although thousands of H3R ligands, some aimed at clinical use, had been optimized in rat, the pharmacological profiles of the recombinant human and rat H3R receptors are different [20]. Thus, the possibility of screening ligands at the human H3R represented a major advance in the field. Molecular studies confirmed that the H3R is coupled to Gi/o proteins. Its activation enhances binding of the GTP analog [35S]GTPγS to cell or brain membranes 21, 22, 23. Activation of recombinant rat and human H3R inhibits cAMP accumulation, enhances arachidonic acid release, and activates the ERK kinase signaling pathway 14, 24.
In different species including human, molecular studies have shown that functional isoforms are generated by deletion of a pseudo-intron that varies in length and is located in the third intracellular loop of the H3R [25]. The distribution and pharmacology of these isoforms are different. Their respective functions in the brain remain unknown, but they might generate heterogeneity of the cerebral H3R [14].
As we review here, the H3R has become a GPCR of choice for studies of constitutive activity and protean agonism. Consistent with the physiological relevance of the process, H3Rs present in the brain show high constitutive activity. Moreover, the high constitutive activity of H3Rs has been used to investigate protean agonism experimentally.
Section snippets
Constitutive activity of H3Rs
Constitutive activity of the rat and human H3R was first recognized through the signaling changes generated by their expression in cells. As compared with wild-type cells, the expression of H3Rs in cell lines enhances arachidonic acid release and [35S]GTPγS binding, and reduces cAMP accumulation 22, 23, 26 (Box 1). As expected, the level of constitutive activity of the H3R at a given density varies with the cell line and signaling pathway [27]. The [35S]GTPγS binding generated by expression of
Protean agonism at H3Rs
The high constitutive activity of H3Rs made possible the experimental demonstration of ‘protean agonism’ in vitro and in vivo. Although it has been classified as a neutral antagonist [14], proxyfan acts in fact as a protean agonist at H3Rs [27]. When proxyfan is compared against histamine (agonist) and ciproxifan (inverse agonist) in various H3R-mediated responses, it shows a spectrum of activity ranging from full agonism to full inverse agonism, depending on the level of H3R constitutive
Therapeutic potential of H3R inverse agonists
The best-studied effect of H3R inverse agonists is to enhance the activity of histamine neurons; thus, the therapeutic interest in these inverse agonists is largely based on the waking, pro-cognitive and anti-obesity roles of brain histamine neurons [14]. This interest has been dedicated for many years to H3R antagonists, most of which have now been reclassified as inverse agonists.
Despite its complexity, the H3R has become an attractive drug target in the central nervous system. Numerous
Concluding remarks
In summary, consistent with the physiological relevance of the process, H3R constitutive activity has a major regulatory role in the brain. It also has a considerable role in regulating the activity of H3R ligands, as shown by the experimental evidence for H3R protean agonism. Protean agonists such as proxyfan are powerful tools with which to investigate active receptor conformations, and they support a multistate model of GPCR activation. H3R inverse agonists targeting important diseases such
Glossary
- Agonist
- a drug that stabilizes the receptor in an active conformation (state). Active conformations couple to G proteins to initiate a response.
- Anorectic inverse agonist
- an inverse agonist that decreases food intake after its administration.
- Autoreceptor
- a receptor through which a neurotransmitter regulates its own release from a neuron. An autoreceptor is a presynaptic receptor located on nerve endings that usually inhibits neurotransmitter release.
- Constitutive activity
- the spontaneous activity
References (68)
Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins
Trends Pharmacol. Sci.
(1993)Pharmacological proteus?
Trends Pharmacol. Sci.
(1995)Evidence for protean agonism of RX 831003 at α2A-adrenoceptors by co-expression with different Gα protein subunits
Neuropharmacology
(2002)The physiology of brain histamine
Prog. Neurobiol.
(2001)A detailed mapping of the histamine H3 receptor and its gene transcripts in rat brain
Neuroscience
(2002)Application of genomics to drug design: the example of the histamine H3 receptor
Eur. Neuropsychopharmacol.
(2001)- et al.
Sensitivity of histamine H3 receptor agonist-stimulated [35S]GTPγS binding to pertussis toxin
Eur. J. Pharmacol.
(1996) Genetic and pharmacological aspects of histamine H3 receptor heterogeneity
Life Sci.
(2003)Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor
Neuropharmacology
(2002)Constitutive activity of H3 autoreceptors modulates histamine synthesis in rat brain through the cAMP/PKA pathway
Neuropharmacology
(2006)
Differential in vivo effects of H3 receptor ligands in a new mouse dipsogenia model
Pharmacol. Biochem. Behav.
The mechanism of spontaneous firing in histamine neurons
Behav. Brain Res.
Histamine modulates high-voltage-activated calcium channels in neurons dissociated from the rat tuberomammillary nucleus
Neuroscience
The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists
Biochem. Pharmacol.
Effect of R-(−)-α-methylhistamine and thioperamide on in vivo release of norepinephrine in the rat hippocampus
Prog. Neuropsychopharmacol. Biol. Psychiatry
In vivo electrophysiological investigations into the role of histamine in the dentate gyrus of the rat
Neuroscience
Histamine H3 and dopamine D2 receptor-mediated [35S]GTPγS binding in rat striatum: evidence for additive effects but lack of interactions
Biochem. Pharmacol.
Characteristics of recombinantly expressed rat and human histamine H3 receptors
Eur. J. Pharmacol.
The H3 receptor protean agonist proxyfan enhances the expression of fear memory in the rat
Neuropharmacology
High antagonist potency of GT-2227 and GT-2331, new histamine H3 receptor antagonists, in two functional models
Eur. J. Pharmacol.
Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor
Eur. J. Pharmacol.
Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup
Behav. Brain Res.
Ligand-selective receptor conformations revisited: the promise and the problem
Trends Pharmacol. Sci.
Use of an inverse agonist radioligand [3H]A-317920 reveals distinct pharmacological profiles of the rat histamine H3 receptor
Neuropharmacology
Histamine H3 receptor antagonists reach out for the clinic
Drug Discov. Today
The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders
Trends Pharmacol. Sci.
Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649
Biochem. Pharmacol.
Histamine and schizophrenia
Int. Rev. Neurobiol.
Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist
Eur. J. Pharmacol.
Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective
Mol. Pharmacol.
Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery
Br. J. Pharmacol.
Protean agonism at α2A-adrenoceptors
Mol. Pharmacol.
Agonist-induced modulation of inverse agonist efficacy at the β2-adrenergic receptor
Mol. Pharmacol.
Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis
J. Pharmacol. Exp. Ther.
Cited by (112)
Structural modifications in the distal, regulatory region of histamine H<inf>3</inf> receptor antagonists leading to the identification of a potent anti-obesity agent
2021, European Journal of Medicinal ChemistryConstitutive activity of 5-HT receptors: Factual analysis
2020, NeuropharmacologyCitation Excerpt :Moreover, the determination of an inverse agonist and antagonist profile is dependent by at least 3 factors: i) the choice of the heterologous system (Schneider and Seifert, 2010), ii) the intracellular signaling pathway considered, leading to the notion of protean ligand (biased agonism) (Arrang et al., 2007; Berg et al., 1998b; Kenakin, 1995a, 2001; 2004; Liu et al., 2019), and iii) the animal species (Arrang et al., 2007; Kenakin and Christopoulos, 2013). Drugs that were often considered as antagonists most of them do display an inverse activity (Gray and Roth, 2001; Kenakin, 2004; Weiner et al., 2001), or even agonist activity on some specific intracellular signaling pathways (Arrang et al., 2007; Clarke et al., 2013) conferring to the neutral antagonist the status of pharmacological gem. If we add to this complexity the factor “selectivity” of the compounds, it is easy to understand that the existence of constitutive activity in native tissue is a complicated task.
Sleep modulating agents
2019, Bioorganic and Medicinal Chemistry LettersCitation Excerpt :Classical pharmacology efforts in the 1980s identified the H3 receptor on histaminergic neurons that modulates the presynaptic release of histamine, thereby affecting wakefulness via changes in histamine levels.138 Due to the constitutive inhibitory activity of the receptor on histamine release, H3 inverse agonists were found to have the appropriate receptor pharmacology to increase wakefulness via increases in histaminergic tone over and above classic histamine antagonists.139,140 The H3 histamine receptor also modulates the release of several other neurotransmitters including GABA, dopamine, serotonin, norepinephrine, glutamine and acetylcholine over and above histamine regulation.
Differential homologous desensitization of the human histamine H<inf>3</inf> receptors of 445 and 365 amino acids expressed in CHO-K1 cells
2018, Neurochemistry InternationalCitation Excerpt :Together, these data discard that the desensitization process was influenced by the biased agonism described for RAMH at the hH3R365 and hH3R445 isoforms expressed in Flp-In-CHO-TREx cells (Riddy et al., 2016). Constitutive activity has been reported for native and cloned H3Rs (Arrang et al., 2007). Our results, based on the cAMP accumulation assay, indicate that both isoforms possess constitutive activity when expressed in CHO-K1 cells, but also that this activity depends on both the ligands and the receptors, suggesting biased inverse agonism at the isoforms (Alonso et al., 2014; Seifert, 2013; Tao, 2014), likely to relate to the differences in chemical interactions of the antagonists/inverse agonists and H3Rs (Jończyk et al., 2017).
Measuring dynamic Eustachian tube function using tympanometry in a pressure chamber: The effect of nasal betahistine application
2019, Journal of Laryngology and OtologyHistamine-3 Receptor Availability and Glutamate Levels in the Brain: A PET-<sup>1</sup>H-MRS Study of Patients With Schizophrenia and Healthy Controls
2024, International Journal of Neuropsychopharmacology